IQVIA Holdings, Inc.

IQVIA was formed in 2016 from the merger of IMS Health and Quintiles Transnational Holdings. IMS Health possessed the world's largest commercial pharmaceutical database — aggregating prescription claims, physician activity, hospital purchasing, and real-world patient data from more than 100,000 data suppliers across 100+ countries. Quintiles was the world's largest contract research organization (CRO), running clinical trials for drug developers globally. Prior to the merger, neither company could fully use the other's core asset: Quintiles ran trials operationally but lacked the data to make patient recruitment and site selection decisions analytically; IMS had rich data assets but no delivery engine to turn them into trial outcomes. The combined entity, IQVIA, was formed explicitly to solve this gap. At formation, IQVIA had approximately $7.6B in combined revenue across technology solutions, research and development outsourcing, and commercial services.

IQVIA invested heavily in building its 'Connected Intelligence' platform — a proprietary technology architecture that fused IMS Health's data assets with Quintiles' trial delivery capabilities:

• Patient-level data integration: Linked anonymized real-world patient data (prescriptions, diagnoses, treatment histories) from the IQVIA database to clinical trial site selection models. This enabled trial sponsors to identify the specific sites and geographies where their target patient population was most concentrated, dramatically improving recruitment rate predictions.
• Site performance analytics: Built predictive models for clinical trial site performance — predicting which investigator sites would enroll at the contracted rate — using historical enrollment data from prior trials in the same indication. Sites were pre-scored before activation, and low-performing sites were replaced earlier in the trial lifecycle.
• Protocol complexity analytics: Developed a Protocol Analyzer tool that scored protocol design complexity against a benchmark database of 50,000+ prior trials. Sponsors received specific recommendations to simplify inclusion/exclusion criteria that were driving recruitment failure, before the trial went live.
• Real-world evidence (RWE) services: Built a clinical trial-to-RWE pipeline, enabling sponsors to extend trial findings with post-approval real-world datasets. This created a continuous measurement framework from development through commercial launch.